Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin’s Lymphoma

Overview

Prospective, multicenter, Phase II trial designed to assess whether intensification of ABVD (dd-ABVD) is feasible and can improve the outcome of patients with early stage Hodgkin Lymphoma.

Full Title of Study: “Dose-dense ABVD as First Line Therapy in Early Stage Unfavorable Hodgkin’s Lymphoma: a Phase II, Prospective, Multi-center Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2015

Detailed Description

Dose-density has been shown to be an important factor for complete remission rate and longterm survival in lymphomas. The aims of this study were to find out whether intensification of ABVD (dd-ABVD) is feasible and can improve the outcome of patients with early stage Hodgkin Lymphoma. In view of emerging data on the role of early PET in defining prognosis in Hodgkin Lymphoma patients, the percentage of FDG-PET (fluorodeoxyglucose positron emission tomography) negativity after two cycle was chosen as the parameter to evaluate dd-ABVD activity.

Interventions

  • Drug: dose dense ABVD
    • dose dense ABVD will be administered intravenously on day 1 and 8 every 21 days Chemotherapy regimen Doxorubicin 25 mg/m2 i.v. day 1 and 8 Bleomycin 10 mg/m2 i.v. day 1 and 8 Vinblastine 6 mg/m2 i.v. day 1 and 8 Dacarbazine 375 mg/m2 i.v. day 1 and 8 Granulocyte colony-stimulating factor (G-CSF): days 9 to 14

Arms, Groups and Cohorts

  • Experimental: dose dense ABVD
    • 1 arm for all patients (dose dense ABVD on day 1 and 8 every 21 days)

Clinical Trial Outcome Measures

Primary Measures

  • Feasibility
    • Time Frame: After 4 dd-ABVD cycles (12 weeks after starting treatment)
    • Proportion of patient with a dose intensity reduction (lower than 85% of planned dose)
  • Activity
    • Time Frame: After 2 dd-ABVD cycles (6 week after starting treatment)
    • Percentage of FDG PET negativity after 2 dd-ABVD cycles will be considered as primary endpoints.

Secondary Measures

  • Overall accuracy of each interim PET interpretation criteria after a minimum follow-up of three years
    • Time Frame: After 3 years of follow-up
    • Concordance between pet results and patients prognosis
  • PFS
    • Time Frame: 2 years from the activation of therapy in the last patient enrolled onto the study.
    • Progression free survival estimate (prognosis outcome)
  • OS
    • Time Frame: 2 years from the activation of therapy in the last patient enrolled onto the study.
    • Overall survival estimate (prognosis outcome)
  • Toxicity
    • Time Frame: 2 years from the activation of therapy in the last patient enrolled onto the study.
    • Proportion of early and late toxicities (G3/4 acute toxicities, secondary malignancies, cardiovascular and pulmonary events, infertility)
  • Predictive Value of each interim PET interpretation criteria after a minimum follow-up of three years
    • Time Frame: After 3 years of follow-up
    • Concordance between pet results and patients prognosis

Participating in This Clinical Trial

Inclusion Criteria

  • Age 18-70 years – Histologically confirmed Hodgkin Lymphoma stage I, II unfavorable according to EORTC (European Organisation for Research and Treatment of Cancer) criteria, with exclusion of stage II B bulky. – Previously untreated – ECOG (Eastern Cooperative Oncology Group) performance status 0 – 2 – Staging with FDG-PET (fluorodeoxyglucose positron emission tomography) – Written informed consent – Adequate liver and renal function (total serum bilirubin < 2.5 x ULN, AST/SGOT and/or ALT/SGPT ≤ 2.5 x upper limit of normal (ULN) or ≤ 5.0 x ULN if the transaminase elevation is due to disease involvement, serum creatinine < 2.5 x ULN) Exclusion Criteria:

  • Concomitant cardiac, pulmonary, neurologic, psychiatric or metabolic severe disease. – Uncontrolled diabetes mellitus (with fasting glucose levels above 200mg/dl) – Other prior malignancies except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast or other cancer from which the patient has been disease-free for ≥ 3 years – Patients with a known history of HIV seropositivity – Active HCV infection (PCR + ; AST> 1.5-2x UN) – Woman who is pregnant or breast feeding. Fertile patients not willing to use effective contraception during the study and 3 months after the end of treatment. Women of childbearing potential (WOCBP) are defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months. – Negative pregnancy test at baseline is required (serum β HCG). – Male patient whose sexual partner(s) are WOCBP who are not willing to use a effective contraception during the study and 3 months after the end of treatment – Nodular lymphocyte prevalence histological subtype

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Fondazione Italiana Linfomi – ETS
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Armando Santoro, M.D., Principal Investigator, Humanitas Cancer Center – Department of Medical Oncology and Haematology

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.